



## PAs and Buprenorphine in Opioid Treatment Programs

Buprenorphine is a Schedule III controlled medication which is commonly used to treat patients with opioid use disorder as part of medication-assisted treatment (MAT). Buprenorphine is an opioid partial agonist, which means the medication produces similar, but weaker, effects to traditional opioid drugs. It also produces a “ceiling effect,” in which the opioid effects level off even if dosage is increased.<sup>1</sup> In the U.S., buprenorphine used for MAT is typically combined with naloxone, which limits misuse and diversion by blocking withdrawal symptoms when taken as prescribed but producing a withdrawal response when tablets are crushed and injected.<sup>2</sup> When used in combination with counseling and behavioral therapy, buprenorphine is considered safe and highly effective in treating individuals who struggle with opioid dependency.<sup>3</sup>

Until recently, buprenorphine was only available through opioid treatment programs (OTPs) certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) or provided by office-based physicians with a waiver from the Drug Enforcement Administration (DEA). In 2016, the Comprehensive Addiction and Recovery Act (CARA) amended federal law to allow PAs to apply for a DEA waiver to prescribe buprenorphine in an office setting. PAs seeking a waiver must complete 24 hours of training and practice in collaboration with a physician who is eligible for a waiver, though the law does not require the physician to actually be waived. PAs who receive the DEA waiver may prescribe buprenorphine for up to 30 patients.

The enactment of CARA is expected to increase access to MAT, especially in areas which currently lack prescribers. However, the new waiver process means PAs who treat patients using MAT must be aware of the requirements for the setting in which they practice. PAs who work in an office setting must follow the new DEA waiver process and ensure they are collaborating with a physician who is waiver-eligible, as required by federal law. At the same time, they should note their state’s laws and regulations. Some states prohibit PAs from practicing or prescribing outside of their collaborating physician’s scope or typical practice, while others have limitations on PAs prescribing buprenorphine or MAT in any circumstance.

PAs who work in SAMHSA-certified OTPs have different requirements. Practitioners at OTPs order and dispense medications (including buprenorphine), but they do not prescribe. PAs that practice in OTPs are not required to have a DEA waiver to order the dispensing of

---

<sup>1</sup> SAMHSA. Buprenorphine <https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine>. Accessed December 19, 2017.

<sup>2</sup> Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. *Drugs*. 2009;69(5): 577-607.

<sup>3</sup> SAMHSA. Buprenorphine <https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine>. Accessed December 19, 2017.

buprenorphine; however, individual OTPs must apply to SAMHSA through their State Opioid Treatment Authority (SOTA) for an exemption to allow PAs to write orders, admit patients, and order the dispensing of approved medications.<sup>4</sup> A list of state SOTAs can be found [here](#). To date, only twelve states have applied for this exemption. More information on seeking a SAMHSA exemption can be found [here](#).

PAs are better-equipped than ever to have a positive impact on the nation's opioid crisis, but it is imperative that PAs seeking to provide access to MAT are aware of the relevant state and federal laws and regulations. For more information, contact [Erika Miller](#), director, AAPA Constituent Organization Outreach & Advocacy.

Last updated: March 2018

---

<sup>4</sup> AAPA. PA Role in Opioid Treatment Programs. [https://www.aapa.org/wp-content/uploads/2017/01/PA\\_Role\\_in\\_Opioid\\_Treatment\\_Programs.pdf](https://www.aapa.org/wp-content/uploads/2017/01/PA_Role_in_Opioid_Treatment_Programs.pdf). Accessed December 19, 2017.